Royal Bank Of Canada Lowers Diaceutics (LON:DXRX) Price Target to GBX 185

Diaceutics (LON:DXRX - Free Report) had its price target cut by Royal Bank Of Canada from GBX 195 ($2.63) to GBX 185 ($2.50) in a research note published on Thursday, MarketBeat.com reports. They currently have an outperform rating on the stock.

Diaceutics Stock Performance

Shares of LON:DXRX traded up GBX 2.50 ($0.03) during midday trading on Thursday, reaching GBX 119 ($1.61). 12,197 shares of the company traded hands, compared to its average volume of 125,377. The company has a quick ratio of 9.92, a current ratio of 4.85 and a debt-to-equity ratio of 0.39. Diaceutics has a 12 month low of GBX 106 ($1.43) and a 12 month high of GBX 151 ($2.04). The firm has a market capitalization of £100.43 million, a price-to-earnings ratio of -35.29 and a beta of 0.58. The firm's fifty day moving average price is GBX 124.79 and its two-hundred day moving average price is GBX 128.57.

Diaceutics (LON:DXRX - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported GBX (2.02) (($0.03)) earnings per share (EPS) for the quarter. Diaceutics had a negative net margin of 10.90% and a negative return on equity of 7.15%. On average, equities analysts expect that Diaceutics will post 1.0107919 earnings per share for the current year.

Insider Transactions at Diaceutics

In related news, insider Peter Keeling sold 500,000 shares of the firm's stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of GBX 126 ($1.70), for a total transaction of £630,000 ($849,858.36). 34.30% of the stock is currently owned by insiders.

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.